home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610339.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
2KB
|
29 lines
Document 0339
DOCN M9610339
TI Enhancing the avidity of a human recombinant anti-HIV-1 monoclonal
antibody through oligomerization.
DT 9601
AU Tsai PK; Burke CJ; Irwin JW; Bruner MW; Tung JS; Hollis GF; Mark GE;
Kessler JA 2nd; Boots LJ; Conley AJ; et al; Department of Pharmaceutical
Research, Merck Research; Laboratories, West Point, PA 19486, USA.
SO J Pharm Sci. 1995 Jul;84(7):866-70. Unique Identifier : AIDSLINE
MED/96057251
AB The oligomerization by chemical cross-linking of a recombinant human
antiviral monoclonal antibody (MAb), r447-1, and its characterization
are described. This MAb binds to an epitope residing in the
hypervariable V3 region of the envelope protein (gp120/160) of HIV-1. A
dimeric form of this MAb displays enhanced avidity and was found to be
capable of neutralizing a greater variety of lymphoid cell
culture-adapted HIV-1 variants and HIV-1 primary isolates than its
monomeric form. The superior binding and breadth of reactivity of this
antibody suggests it may have utility as a therapeutic and/or
prophylactic agent, if it possesses an appropriate safety and
immunogenicity profile.
DE Antibodies, Monoclonal/*GENETICS Antigens/IMMUNOLOGY Chromatography
Human HIV-1/*IMMUNOLOGY Molecular Structure Proteins/METABOLISM
Recombination, Genetic Time Factors JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).